Journal
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY
Volume 43, Issue 2-3, Pages 389-400Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s10295-015-1677-7
Keywords
FK506; Biological activity; Biosynthetic pathway; Production improvement; FK506 analogs; Genetic engineering
Categories
Funding
- Basic Science Research Program through National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MISP) [2013R1A2A1A01014230]
- Intelligent Synthetic Biology Center of the Global Frontier Project - MISP [20110031961]
- Advanced Production Technology Development Program
- High Value-added Food Technology Development Program, Ministry of Agriculture, Food and Rural Affairs, Republic of Korea
- National Research Foundation of Korea [2013R1A2A1A01014230] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
FK506, a 23-membered macrolide produced by several Streptomyces species, is an immunosuppressant widely used to prevent the rejection of transplanted organs. In addition, FK506 and its analogs possess numerous promising therapeutic potentials including antifungal, neuroprotective, and neuroregenerative activities. Herein, we introduce the biological activities and mechanisms of action of FK506 and discuss recent progress made in understanding its biosynthetic pathway, improving production, and in the mutasynthesis of diverse analogs. Perspectives highlighting further strain improvement and structural diversification aimed at generating more analogs with improved pharmaceutical properties will be emphasized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
